|
Improving venous thromboembolism (VTE) prophylaxis for hospitalized malignant hematology/bone marrow transplant (heme/BMT) patients. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Actelion (I); Boston Scientific (I); Gilead Sciences (I) |
Consulting or Advisory Role - Actelion (I); Boston Scientific (I); Gilead Sciences (I) |
Speakers' Bureau - Actelion (I) |
Research Funding - Sunesis Pharmaceuticals |
Expert Testimony - Kaiser Permanente |
|
|
No Relationships to Disclose |
|
|
Research Funding - Clovis Oncology (I); Daiichi Sankyo |